AN2 Therapeutics, Inc.
NASDAQ:ANTXBiotechnology
+$0.04 today
- Market cap
- $187.82M
- Beta
- -0.98
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$1.01
Volume 0.97M
Average 0.29M
ANTX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
AN2 Therapeutics, Inc.NASDAQ: ANTX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $10.03M (cash outflow) fell 5.8% year over year, ahead of the -23.8% change in trailing-twelve-month net income. Sequentially, it rose 15.1% from the prior quarter. Over 3 fiscal years it compounded at -4.9% a year.
Context
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$29.01M (-17.5%) for the fiscal year ending Dec 2026, a step up from the -31.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$10.03M+15.1% QoQ
- Last fiscal yearDec 2025
- -$35.17M-31.5% YoY
- LTMMar 2026
- -$34.55M-23.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -5.8% | +21.2% | +27.1 pp |
| 1 year | -31.5% | -17.5% | +13.9 pp |
| 3-year CAGR | -4.9% | -4.3% | +0.6 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (35.17M) USD
- Year-over-year change
- +31.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (35.17M) | +31.5% |
| FY2024 | 2024-12-31 | (51.32M) | +20.7% |
| FY2023 | 2023-12-31 | (64.73M) | -58.1% |
| FY2022 | 2022-12-31 | (40.96M) | -90.1% |
| FY2021 | 2021-12-31 | (21.54M) | — |
Net Income vs competitors
How ANTX compares with its peers on the latest reported figures
- ANTX's LTM Mar 2026 net income of $34.55M is the 3rd largest of the 6 companies compared; the peer median is $33.04M.
- Its year-over-year change of -23.8% is the 5th highest of 6, against a peer median of +79.8%.
- Over three fiscal years its annual growth of -4.9% compares with a peer median of -9.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $71.75M | +93.6% | — | — | |
| LTM Mar 2026 | $55.99M | -14.8% | +8.2% | — | |
| LTM Mar 2026 | $34.55M | -23.8% | -4.9% | — | |
| LTM Mar 2026 | $33.24M | +155.6% | — | 61.9% | |
| LTM Jun 2026 | $33.04M | +79.8% | -20.2% | 33044.0% | |
| LTM Mar 2026 | $17.83M | -73.0% | -9.9% | 48.0% | |
| Peer median (excluding ANTX) | $33.04M | +79.8% | -9.9% | 61.9% | |
Competitors are the stored peer set for ANTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (21.54M) | (40.96M) | (64.73M) | (51.32M) | (35.17M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 974K | 4.39M | 8.41M | 8.34M | 6.25M |
| Change in Working Capital | 32K | 3.72M | 5.83M | (3M) | 164K |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 417K | 2.5M | 553K | 641K | (296K) |
| Other Working Capital | (385K) | 1.22M | 5.28M | (3.64M) | 460K |
| Other Non-Cash Items | 53K | (615K) | (2.8M) | (3.28M) | (1.07M) |
| Operating Cash Flow | (20.48M) | (33.46M) | (53.29M) | (49.26M) | (29.83M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (77.27M) | (93.84M) | (132.18M) | (46.75M) | (46.19M) |
| Sales of Investments | 27.25M | 72.07M | 88.9M | 101.34M | 74.5M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (50.02M) | (21.77M) | (43.28M) | 54.59M | 28.31M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 70.37M | 84.53M | 372K | 113K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.2M) | (11K) | 465K | 0 | 0 |
| Financing Cash Flow | 78.54M | 70.36M | 84.99M | 372K | 113K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 8.03M | 15.12M | (11.57M) | 5.7M | (1.41M) |
| Free Cash Flow | (20.48M) | (33.46M) | (53.29M) | (49.26M) | (29.83M) |
AN2 Therapeutics, Inc.
NASDAQ:ANTX
Intrinsic Alpha fair value
Locked
Current Price
$4.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.